Last checked at 17 Dec 2023 15:16
PRESS: GSK looks for deals in China as rebuilds relationship
(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades8,855
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,733.50
Bid:
1,732.50
Ask:
1,733.00
Change:
5.00 (0.29%)
Spread:
0.50 (0.029%)
Open:
1,733.00
High:
1,739.50
Low:
1,724.50
Prev. Close:
1,728.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.GSK bets $300m on tie-up with gene-tester 23andMe
Wed, 25th Jul 2018 11:06
(Sharecast News) - GlaxoSmithKline has invested $300m (£228m) in 23andMe, a Silicon Valley gene-testing company, as the UK drugs giant looks to genetics to improve growth in its pharmaceuticals division. Announcing second-quarter results, GSK said the deal would give it exclusive access to 23andMe's DNA database as a resource for finding new treatments.GSK said the deal was an important part of its new approach to research focused on the biology of the immune system and genetic evidence.The four-year agreement will combine 23andMe's genetic database with GSK's medical experience and commercial heft.23andMe has more than 5m customers, more than 80% of which have agreed to allow their data to be used for research.The Google-backed US company is known for test kits that let users find out about their genetic roots with a sample of saliva. But it also has a research and development division that has come up with early stage therapies.The companies will combine existing projects and form a joint drug discovery team to identify target diseases based on the strength of biological evidence.Hal Barron, who joined GSK as chief scientist in January, said: "Drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines. Partnering with 23andMe...will help to shift our research and development organisation to be 'driven by genetics', and increase the impact GSK can have on patients."Project costs will be split equally with room for both sides to reduce its share for a particular programme. GSK has taken a $300m equity stake in 23andMe.As far as the results are concerned, GSK said group sales in the second quarter rose 4% excluding currency swings to £7.3bn. Pharmaceutical sales were the weakest of GSK's three divisions, rising 1% to £4.2bn compared with 16% from vaccines and 3% from healthcare at constant currency. GSK announced a plan to spend £1.7bn over thee years to save £400m a year in supply chain and administration costsEmma Walmsley, GSK's chief executive, said: "GSK has delivered encouraging results across the company this quarter with CER (constant exchange rate) sales growth in each of our three global businesses. We have announced the start of a new approach to R&D which aims to capitalise on the assets we have in our promising early-stage pipeline and build the next wave of growth for GSK."The company increased its target for adjusted earnings growth to 7-10% if no generic competitor for its Advair product hits the US market in 2018.
More News
15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:22
TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine
(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:24
GSK seeks to extend RSV vaccine approval in Japan
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read more11 Dec 2023 08:28
GSK drug gets EU marketing backing for form of endometrial cancer
(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more11 Dec 2023 07:23
GSK endometrial cancer treatment gets Europe authorisation
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read more7 Dec 2023 12:54
THG backer Kelso pushes for demerger to trim "inherent" valuation gap
(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more27 Nov 2023 09:00
GSK announces positive results from Blenrep phase 3 blood cancer trial
(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.
Read more27 Nov 2023 08:02
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more